Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

DOI Full Paper Access

111

Citations

13

References

2021

Year

Brett King, Justin Ko, Seth Forman, Manabu Ohyama, Natasha Atanaskova Mesinkovska, Guanglei Yu, Jill Shwed McCollam, Margaret Gamalo, Jonathan Janes, Emily Edson‐Heredia,

Journal of the American Academy of Dermatology

Abstract

These results support the efficacy and safety of baricitinib in patients with ≥50% scalp hair loss.

References

	Year	Citations

Page 1